Controls serum phosphorus. ANDA 215998, held by Shandong Xinhua. Sevelamer Carbonate.
As of Nov 16, 2026, ANDA 215998 (Sevelamer Carbonate), held by Shandong Xinhua, was first approved by FDA on Oct 24, 2024, with 0 approved supplements and 0 published complete response letters.
Sevelamer carbonate tablets are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 24, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sevelamer Carbonate800MG · tablet;oral | Sevelamer Carbonate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters